Skip to main content
PLOS One logoLink to PLOS One
. 2023 Nov 28;18(11):e0294142. doi: 10.1371/journal.pone.0294142

TLR2 mediates renal apoptosis in neonatal mice subjected experimentally to obstructive nephropathy

Maja Wyczanska 1,#, Jana Rohling 1,#, Ursula Keller 1, Marcus R Benz 2, Carsten Kirschning 3, Bärbel Lange-Sperandio 1,*
Editor: Franziska Theilig4
PMCID: PMC10684073  PMID: 38015955

Abstract

Urinary tract obstruction during renal development leads to inflammation, tubular apoptosis, and interstitial fibrosis. Toll like receptors (TLRs) expressed on leukocytes, myofibroblasts and renal cells play a central role in acute inflammation. TLR2 is activated by endogenous danger signals in the kidney; its contribution to renal injury in early life is still a controversial topic. We analyzed TLR2 for a potential role in the neonatal mouse model of congenital obstructive nephropathy. Inborn obstructive nephropathies are a leading cause of end-stage kidney disease in children. Thus, newborn Tlr2-/- and wild type (WT) C57BL/6 mice were subjected to complete unilateral ureteral obstruction (UUO) or sham-operation on the 2nd day of life. The neonatal kidneys were harvested and analyzed at days 7 and 14 of life. Relative expression levels of TLR2, caspase-8, Bcl-2, Bax, GSDMD, GSDME, HMGB1, TNF, galectin-3, α-SMA, MMP-2, and TGF-β proteins were quantified semi-quantitatively by immunoblot analyses. Tubular apoptosis, proliferation, macrophage- and T-cell infiltration, tubular atrophy, and interstitial fibrosis were analyzed immunohistochemically. Neonatal Tlr2-/- mice kidneys exhibited less tubular and interstitial apoptosis as compared to those of WT C57BL/6 mice after UUO. UUO induced neonatally did trigger pyroptosis in kidneys, however to similar degrees in Tlr2-/- and WT mice. Also, tubular atrophy, interstitial fibrosis, tubular proliferation, as well as macrophage and T-cell infiltration were unremarkable. We conclude that while TLR2 mediates apoptosis in the kidneys of neonatal mice subjected to UUO, leukocyte recruitment, interstitial fibrosis, and consequent neonatal obstructive nephropathy might lack a TLR2 involvement.

Introduction

Congenital obstructive nephropathy is a frequent cause of chronic kidney disease in infants and children [1, 2]. Inborn obstruction of the urinary tract impairs renal growth and development and leads to reduced nephron numbers. The reduction of nephrons corresponds with a lifelong risk of end stage kidney disease [3]. Unilateral ureteral obstruction (UUO) in neonatal mice at the second day of life serves as a model for congenital obstructive nephropathy. It studies the effects of urinary tract obstruction on renal development, as nephrogenesis in mice finishes postnatally 2–3 weeks after birth [4]. Contrary, in humans nephrogenesis finishes in utero at 34–36 weeks of gestation. Neonatal UUO elicits tubular apoptosis, renal inflammation, and interstitial fibrosis, which contribute to a loss of nephron mass in the kidney [5]. Inflammatory macrophages, which produce pro-inflammatory cytokines like tumor necrosis factor (TNF), are key players in this process [6]. Toll like receptors (TLRs) are a family of innate pattern recognition receptors. E.g. TLR2 and TLR4 are expressed on leukocytes, myofibroblasts and renal cells which often play a central role in acute inflammation as major sources of pro-inflammatory chemokines and cytokines [79]. Besides being implicated as cellular pathogen-associated molecular pattern sensors, TLR might also bind danger-associated molecular patterns (DAMPs) released upon sterile damage of tissue and thus being of endogenous origin [10]. Cognate ligand activated TLRs initiate intracellular signaling cascades such as through myeloid differentiation primary response gene (MyD88)-dependent phosphorylation of MAPK towards activation of nuclear factors such as activating protein-1 (AP-1) and NF-κB [11]. TLRs have been implicated in various renal diseases, including ischemia-reperfusion injury (IRI), wherein endogenous TLR2 and TLR4 ligands are thought to be released from the renal epithelium [8, 12]. For instance, adult Tlr2-/- mice displayed in the IRI model ameliorated kidney inflammation and injury [13]. TLR2 also influenced renal fibrosis, a hallmark of UUO [14].

TLR2 forms heterodimers with TLR1 or TLR6, as well as a variety of further receptors for recognition of diverse ligands [15]. It plays a central role in the innate immune signaling in renal disease [8, 1618]. During a bacterial infection, TLR2 signals for apoptosis through MyD88 via a pathway involving caspase-8 [19]. High mobility group box 1 (HMGB1) might carry DAMPs that might activate TLR2 [20]. HMGB1 is mostly associated with TLR4 [20, 21]. However, the release of HMGB1 into extracellular fluid also initiates immune responses through TLR2 [22]. Various reports implicate HMGB1 as an important role holder in the pathogenesis of kidney diseases by affecting renal epithelial cell apoptosis, kidney tissue fibrosis, and inflammation [22]. HMGB1 can also trigger pyroptosis, a regulated necrotic cell death, which involves inflammasome activities [23]. Inflammasomes can be activated by DAMPs towards cleavage of gasdermin (GSDM) D or E and consequent cell rupture and release of pro-inflammatory alarmins [23, 24]. The role of TLR2 in the UUO model, inflammatory cell death and fibrosis is being discussed controversially. Renal function of adult Tlr2-/- mice is enhanced as compared to WT controls while TH2 cytokine production and renal fibrosis following UUO are reduced [25]. Here, we comparatively analyzed Tlr2-/- mice for the first time in a neonatal mouse model of congenital obstructive nephropathy.

Materials and methods

Experimental protocol

The Tlr2-/- mouse strain used (and crossed with other Tlr ko strains) has been generated by Deltagen, Cal, USA, and provided to CK through Tularik (merged into Amgen in the aftermath) [26]. Tlr2-/- mice and WT mice (C57BL/6) were subjected to complete left ureteral obstruction or sham operation under general anesthesia with isoflurane (3–5% v/v) and oxygen (0.8 L/min) on the second day of life, as described before [27]. The animals received carprofen to alleviate possible pain after the surgery. The sex distribution was equal in both groups. After recovery, neonatal mice were returned to their mothers until sacrifice on day 7 and 14 of life. The animals were sacrificed by cervical dislocation. All experiments were performed according to national animal protection laws and the guidelines of animal experimentation established and approved by the Regierungspräsidium von Oberbayern (Az 55.2-1-54-2531-136-06).

Identification of infiltrating macrophages and T-lymphocytes

The abundance of infiltrating macrophages and T-lymphocytes in the neonatal kidney was examined by immunohistochemistry. Formalin-fixed, paraffin-embedded kidney sections were subjected to antigen retrieval and incubated with either rat anti-mouse MAC-2 (galectin-3) antibody against macrophages (Cedarlane Laboratories, Canada, CL8942AP, 1:500) or anti- CD3 antibody against T-lymphocytes (Bio-Rad AbD Serotec GmbH, Germany, MCA1477, 1:50). Specificity was assessed through simultaneous staining of control sections with an unspecific, species-controlled primary antibody. Biotinylated horse anti-mouse IgG (Vector Laboratories, CA) was used as secondary antibody. Sections were incubated with ABC reagent, detected with DAB (Vectastain, Vector Laboratories, CA) and counterstained with methylene blue or hematoxylin. Images were taken using the LEICA DM1000 microscope and the digital camera (LEICA ICC50HD, Germany). Macrophages and CD3-positive lymphocytes in cortex and medulla were counted in twenty non-overlapping high-power fields at x400 magnification and were analyzed in a blinded manner (n = 8 in each group). Data were expressed as the mean score ± SEM per 20 high-power fields.

Detection of apoptosis and proliferation

Apoptotic cells were detected by the terminal deoxynucleotidyl transferase (TdT)- mediated dUTP-biotin nick end labeling (TUNEL) assay, as described before [5]. Briefly, 4% formalin-fixed tissue sections were deparaffinized and rehydrated in ethanol, followed by incubation with proteinase K. After quenching, equilibration buffer and working strength enzyme (ApopTag Peroxidase In Situ Apoptosis Detection Kit, Millipore, MA) were applied. Cells were regarded as TUNEL-positive if their nuclei were stained black and displayed typical apoptotic morphology. Apoptosis in each kidney was calculated by counting the number of TUNEL-positive tubular and interstitial cells in 20 sequentially selected fields at x400 magnification in a blinded fashion and expressed as the mean number ± SEM per 20 high-power fields using the LEICA DM1000 microscope and the digital camera (LEICA ICC50HD, Germany). For detection of proliferation formalin-fixed, paraffin-embedded kidney sections were subjected to antigen retrieval and incubated with mouse anti-rat Ki67 antibody (Dako, # M7248, Agilent Technologies, CA) at 1:50). Sections were incubated with ABC reagent, detected with DAB (Vectastain, Vector Laboratories, CA) and counterstained with hematoxylin. Digital images of the sections (n = 8 in each group) were superimposed on a grid, and the number of dark brown Ki67 positive nuclei was recorded for each field. Proliferating tubular and interstitial cells in cortex and medulla were counted in twenty non-overlapping high-power fields at x400 magnification and were analyzed in a blinded manner using the LEICA DM1000 microscope and the digital camera (LEICA ICC50HD, Germany). Data were expressed as the mean score + SEM per 20 high-power fields.

Measurement of tubular atrophy

Kidney sections were stained with periodic acid Schiff for assessment of tubular basement membranes, and tubular atrophy was determined as described previously [5]. Atrophic tubules were identified by their thickened and sometimes duplicated or wrinkled basement membranes. Digital images of the sections (n = 8 in each group) were superimposed on a grid, and the number of atrophic tubules was recorded for each field. Twenty non-overlapping high-power fields at x400 magnification were analyzed in a blinded fashion. Data were expressed as the mean score ± SEM per 20 high power fields.

Measurement of interstitial fibrosis

Interstitial collagen deposition was measured in Masson’s trichrome-stained sections. Digital images of the sections were superimposed on a grid, and the number of grid points overlapping interstitial blue-staining collagen was recorded for each field in a blinded manner. In addition, formalin-fixed and paraffin embedded sections were subjected to antigen retrieval and incubated with mouse anti-mouse α-smooth muscle actin antibody (Sigma Aldrich MO851, Germany, A2547, 1:5000) as shown before [28]. Biotinylated donkey anti goat IgG and horse anti-mouse IgG (Santa Cruz, Germany) were used as secondary antibodies. Sections were incubated with ABC reagent, detected with DAB (Vectastain, Vector Laboratories, CA) and counterstained with hematoxylin. Digital images of the sections (n = 8 in each group) were superimposed on a grid, and the number of grid points overlapping collagen I fibers or α-smooth muscle actin fibers was recorded for each field. Twenty non-overlapping high-power fields at x400 magnification were analyzed in a blinded fashion. Data were expressed as the mean score ± SEM per 20 high power fields.

Western immunoblotting

Kidneys of UUO and control mice were harvested on 7 and 14 days of life (n = 3 in each group) as described previously [5]. Neonatal kidneys were homogenized in protein lysis buffer (Tris 50 mM, Na4P2O3 1 mM, 2% SDS) containing protease inhibitor cocktail (Roche, Switzerland, #1836153). The protein content of the supernatants was measured using the BCA Protein Assay Kit (Pierce Biotechnology, MA, #23225). 20 μg of protein were separated on polyacrylamide gels at 160 V for 45 min and blotted onto nitrocellulose membranes (0,1 A per gel, 120 min). After blocking antibody-specific for 2 h in Tris-buffered saline with Tween-20 containing 5% nonfat dry milk and/or BSA, blots were incubated with primary antibodies 2 h at room temperature or at 4°C overnight. TLR2 antibody (ThermoFisher Scientific, MA, #MA5-32787, 1:1000), Caspase-8 antibody (Cell Signaling Technology, MA, #4927, 1:1000), Bcl-2 antibody (Santa Cruz, Germany, sc7382, 1:200), Bax antibody (Cell Signaling Technology, MA, #27725, 1:1000), GSDMD antibody (Cell Signaling Technology, MA, #39754, 1:1000), GSDME antibody (Abcam, UK, ab215191, 1:500), HMGB1 antibody (Abcam, UK, ab18256, 1:1000), TNF antibody (Cell Signaling Technology, MA, #3707, 1:500), Galectin-3 antibody (Santa Cruz, Germany, sc19283, 1:500), α-SMA antibody (Sigma Aldrich, Germany, A2547, 1:5000), MMP-2 antibody (Santa Cruz, Germany, sc10736, 1:1000), TGF-β (Cell Signaling Technology, MA, #3711, 1:1000) were used for western blot analysis. GAPDH (DUNN Labortechnik, Germany, H86540M, 1:40000) was used as an internal loading control and to normalize samples. Blots were washed with Tris-buffered saline with Tween-20 and incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. Immune complexes were detected using enhanced chemiluminescence method. Blots were exposed to x-ray films (Kodak, Germany), the films were scanned, and protein bands were quantified using the densitometry program Image J. Each band represents one single neonatal mouse kidney. The uncropped gel images can be found in S1 Raw images.

Statistical analysis

Data are presented as mean ± standard error. Comparisons between groups were made using one-way analysis of variance followed by the Student-Newman-Keuls test. Comparisons between left and right kidneys were performed using the Students t-test for paired data. Statistical significance was defined as p < 0.05.

Results

Neonatal UUO induces protein expression of TLR2

To measure the protein expression of TLR2 after UUO, we performed a western blot analysis of UUO and sham-operated kidneys of neonatal WT mice. Following UUO renal TLR2 protein expression increased significantly on day 14 of life in comparison to sham-operated controls (Fig 1A). We observed that as a response to the injury. TLR2 expression levels in neonatal WT-kidneys were increased. This analysis was also used to confirm that Tlr2-/- mice indeed did not express TLR2 (Fig 1B).

Fig 1. Neonatal unilateral ureteral obstruction induces the expression of TLR2.

Fig 1

Neonatal WT mice were subjected to UUO or sham operation and their kidneys were harvested on d7 and d14. Lysates of whole kidneys were applied to SDS PAGE and consequent western blot analyses. The TLR2 expression level was significantly higher in UUO kidneys as compared to sham-operated controls on d14 (A). Tlr2-/- mice did not express TLR2 (B). n = 4; *p<0,05. Data are presented as mean +/- SEM.

TLR2 mediates tubular and interstitial apoptosis in neonatal kidneys with UUO

We next investigated tubular and interstitial apoptosis in neonatal kidneys from Tlr2-/- and WT mice having undergone UUO using TUNEL staining. Tubular apoptosis increased significantly in the obstructed kidneys at day 7 and 14 of life (Fig 2A–2C). TUNEL positive cells were mainly present in dilated distal tubules of the neonatal kidney. Tlr2-/- mice showed less tubular apoptosis compared to WT (Fig 2A–2C). Tubular apoptosis in Tlr2-/- mice was reduced on day 7 and day 14 of life by 41% and 30%, respectively (Fig 2C). Interstitial apoptosis increased following UUO and Tlr2-/- mice showed less interstitial apoptosis compared to WT (Fig 2D). Interstitial apoptosis in Tlr2-/- kidneys after UUO was reduced on day 7 and day 14 by 41% and 16%, respectively (Fig 2D). Glomerular apoptosis increased following UUO, but without significant differences between Tlr2-/- and WT kidneys (Fig 2E). Apoptosis was also measured by caspase-8 protein expression using western blot (Fig 2F). Cleavage of caspase-8 indicates apoptosis [29]. Both WT and Tlr2-/- mice showed reduced caspase-8 expression indicating apoptotic cell death after UUO (Fig 2F). However, caspase-8 expression was not significantly different between WT and Tlr2-/- mice (Fig 2F), which may be explained by the lack of compartment-specific analysis of the neonatal kidney. For further analysis of cell death in our model we analyzed the anti-apoptotic marker Bcl-2 and the pro-apoptotic marker Bax using western blot (Fig 3). Neonatal Tlr2-/- mice showed a higher expression of Bcl-2 at day 14 in comparison to WT (Fig 3A), confirming that TLR2 mediates apoptosis in the neonatal model of obstructive nephropathy. Bax expression increased following UUO at day 14, without significant differences between Tlr2-/- and WT kidneys.

Fig 2. Tubular and interstitial apoptosis in Tlr2-/- mice with UUO.

Fig 2

UUO was performed on the second day of life. Apoptotic cells were detected by TUNEL staining in sections. TUNEL-positive cells in WT (A) and Tlr2-/- (B) neonatal mouse kidneys appeared predominantly in distal tubules and in the interstitium. Arrows indicate tubular apoptotic cells. Quantification indicates significant decreases of numbers of TUNEL-positive tubular (C) and interstitial (D) cells in Tlr2-/- as compared to WT UUO kidneys. The number of apoptotic nuclei in glomeruli did not differ between Tlr2-/- and WT specimen (E); n = 8. Whole kidneys were lysed for western blot analyses (F). Caspase-8 expression was reduced in UUO-kidneys indicating apoptosis following ureteral obstruction. Significant differences between WT and Tlr2-/- were not observed (F). Results are indicated as x-fold relative to sham-operated controls. n = 3 (Western Blot); *p<0,05. Data are presented as mean +/- SEM. Bar = 100μm. Standalone * represents significant differences between Sham and UUO results.

Fig 3. Tlr2-/- mice show increased renal Bcl-2 expression in comparison to WT following UUO.

Fig 3

Neonatal mice were subjected to UUO or sham operation. Western blot analysis was performed at day 7 and 14 of life. UUO induced the expression of Bcl-2 in Tlr2-/-, but not in WT kidneys at day 14 (A). UUO induced expression of Bax in the neonatal kidney without significant differences between WT and Tlr2-/- (B). Results are indicated as x-fold relative to sham-operated controls. n = 3; *p<0,05. Data are presented as mean +/- SEM. Standalone * represents significant differences between Sham and UUO results.

Pyroptosis generally increased after neonatal UUO, yet its grades in WT are indistinguishable from those of Tlr2-/- murine specimen

To measure the potential impact of TLR2 expression on pyroptosis upon UUO versus samples from sham-operated mice, abundance of cleaved GSDMD and full-length GSDME expression in respective kidneys at day 7 and 14 of life were measured by immunoblotting (Fig 4A and 4B). While the abundance of cleaved GSDMD increased due to the obstruction in samples of both phenotypes at d14 (Fig 4A), that of full-length GSDME decreased after UUO (Fig 4B) as if pyroptosis became operative upon UUO. However, WT and Tlr2-/- mice borne specimen were undistinguishable in this regard (Fig 4A and 4B). Thus, TLR2 is not involved in pyroptosis after ureteral obstruction in the neonatal kidney. Additionally, we analyzed the expression of the pyroptosis markers HMGB1 and TNF in UUO- and sham-operated neonatal kidneys at day 7 and 14 of life (Fig 4C and 4D). Expression levels of both proteins remained constant throughout the analysis period and were indistinguishable in specimen of both genotypes (Fig 4C and 4D). We conclude that TLR2 has no impact on pyroptosis, HMGB1 and TNF expression in the neonatal kidney having been subjected to UUO.

Fig 4. Pyroptosis increases after UUO.

Fig 4

Neonatal mice were subjected to UUO or sham operation. Whole kidneys were processed for western blot analysis at day 7 and 14 of life. UUO induced cleaved GSDMD expression (A) and full-length GSDME cleavage (B), but with no significant differences between WT and Tlr2-/-. Pyroptosis markers HMGB1 (C) and TNF-α (D) did not show significant differences between WT and Tlr2-/-. Results are indicated as x-fold relative to sham-operated controls. n = 3; *p<0,05. Data are presented as mean +/- SEM. Standalone * represents significant differences between Sham and UUO results.

Proliferation decreased and tubular atrophy increased in neonatal kidneys after UUO, without significant differences between Tlr2-/- and WT mice

Proliferation in neonatal Tlr2-/- and WT mouse kidneys was measured using Ki67 staining in obstructed and sham-operated kidneys at day 7 and 14 of life (Fig 5A–5C). Following obstruction, proliferation decreased significantly, but without a significant difference between WT and Tlr2-/- mice (Fig 5C). To measure tubular atrophy, a Periodic Acid Schiff (PAS) staining of neonatal WT and Tlr2-/- kidneys was performed after UUO at day 7 and 14 of life (Fig 5D–5F). Tubular atrophy increased at d7 and d14 in UUO kidneys and was more prominent in proximal than distal tubules following UUO. Between WT and Tlr2-/- mice no significant differences in tubular atrophy could be observed (Fig 5F). We conclude that TLR2 does not influence proliferation or tubular atrophy in the neonatal kidney with UUO.

Fig 5. Analysis of tubular proliferation and atrophy in neonatal mice following UUO.

Fig 5

Immunohistochemical staining of Ki67 (A and B) and proximal (prox) and distal (dist) atrophic tubules (D and E) in neonatal UUO WT (A and D) and Tlr2-/- (B and E) mice at day 7. Quantification of Ki67-positive tubular cells in UUO-kidneys (C) shows a decrease following UUO without significant differences between WT and Tlr2-/-. Quantitative analysis of tubular atrophy in UUO-kidneys on day 7 and day 14 (F) shows an increase of tubular atrophy in proximal and distal tubules following UUO, but no significant differences between WT and Tlr2-/- mice in neither compartment. Results are indicated as x-fold increase above sham operated control in 20 hpfs; n = 8. Data are presented as mean +/- SEM. Bar = 100μm. Standalone * represents significant differences between Sham and UUO results.

M2 macrophage infiltration, T-lymphocyte infiltration and fibrosis increased after UUO but were not different between Tlr2-/- and WT mice

Influence of TLR2 on M2 macrophage infiltration in neonatal Tlr2-/- and WT mouse kidneys with UUO was measured using galectin-3 staining (Fig 6A–6C) and galectin-3 protein expression using western blot (Fig 7A). Increased expression of interstitial galectin-3 is a feature of the regenerative anti-inflammatory alternative (M2) macrophage phenotype. UUO induced a vast M2 macrophage infiltration in the interstitium of neonatal Tlr2-/- and WT kidneys, 10-fold at d14, but without significant differences between the two lines (Fig 6A–6C). UUO induced a marked galectin-3 expression in the neonatal kidneys but was not different between Tlr2-/- and WT mice (Fig 7A). T-lymphocyte infiltration was assessed by CD3 staining (Fig 6D–6F). UUO induced CD3 positive T-cell-infiltration in neonatal kidneys of WT and Tlr2-/- mice, at d7 and d14 (Fig 6D–6F). No significant differences between WT and Tlr2-/- kidneys could be observed (Fig 6F). We conclude that TLR2 does not have an impact on the M2 macrophage and T-lymphocyte infiltration in the neonatal kidney with UUO. To study interstitial fibrosis in WT and Tlr2-/- mice after neonatal UUO, Masson’s Trichrome and α-smooth muscle actin (α-SMA) staining of kidney sections were performed (Fig 6G–6L). Additionally, protein expression of α-SMA, matrix metalloproteinase-2 (MMP-2), and transforming growth factor (TGF)-β was measured by western blot (Fig 7B–7D). Interstitial collagen deposition measured by the Masson’s Trichrome staining, increased after UUO in both WT and Tlr2-/- mice (Fig 6G–6I). The abundance of α-SMA increased at d7 and d14 after UUO but was not different in Tlr2-/- mice in comparison to WT mice (Fig 6J–6L). Following neonatal UUO, α-SMA expression increased significantly at d7 and d14 (Fig 7B), but without significant differences between WT and Tlr2-/- kidneys. MMP-2 expression increased significantly after ureteral obstruction at d7 and d14 in WT and Tlr2-/- mice (Fig 7D), with a slightly increasing trend for Tlr2-/- kidneys, but without significant differences between the two lines. UUO induced increased TGF-β-expression (Fig 7D) in the neonatal kidneys, but Tlr2-/- mice were not significantly different from WT mice. We therefore conclude that TLR2 does not attenuate renal fibrosis in the neonatal kidney with UUO.

Fig 6. Immune cell infiltration and fibrosis in neonatal UUO kidneys.

Fig 6

Immunohistological staining for galectin-3, a M2 macrophage marker, of WT (A) and Tlr2-/- (B) mice on day 14. Quantitative analysis shows that UUO induced interstitial galectin-3 positive macrophage infiltration (arrow) in neonatal kidneys (C), but without significant differences between WT and Tlr2-/- mice. Immunohistological staining for CD3 (arrow), a T-lymphocyte marker, of WT (D) and Tlr2-/- (E) mice on day 14. Quantitative analysis shows CD3 positive T-cell infiltration in neonatal kidneys following UUO (F) without significant differences between WT and Tlr2-/- mice. Renal sections of UUO- and sham-operated were stained for Masson’s Trichrome (MT) at 7 and 14 days of life. UUO induced collagen deposition in neonatal kidneys of WT (G) and Tlr2-/- mice (H) on day 14. Renal sections of UUO- and sham-operated mice were stained for α-SMA at 7 and 14 days of life. UUO induced α-SMA expression in neonatal kidneys of WT (J) and Tlr2-/- mice (K) on day 14. Analysis of α-SMA positive myofibroblasts in UUO-kidneys on day 7 and 14 (L) showed no significant differences between the two groups. Results are indicated as x-fold increase above sham operated control in 20 hpfs (x400); n = 8. Data are presented as mean +/- SEM. Bar = 100μm. Standalone * represents significant differences between Sham and UUO results.

Fig 7. Protein expression of macrophage and fibrosis markers after UUO.

Fig 7

Neonatal mice were subjected to UUO or sham operation. Whole kidneys were processed for western blot analysis at day 7 and 14. UUO induced galectin-3 expression in neonatal UUO kidneys, without significant differences between WT and Tlr2-/- kidneys (A). UUO induced the expression of the fibrotic markers α-SMA (B), MMP-2 (C) and TGF-β (D), but without significant differences between Tlr2-/- and WT mice at day 7 and 14 of life. Expression is indicated as x-fold increase above sham operated control, n = 3. Data are presented as mean +/- SEM. Standalone * represents significant differences between Sham and UUO results.

Discussion

Our study indicates involvement of TLR2 in the mediation of apoptosis in the early life developing murine kidney suffering from ureteral obstruction. This result is of potential relevance because the pattern recognition receptor TLR2 is an element of innate immunity, which drives various kidney diseases elicited experimentally in animal models [8, 30]. Exemplarily, TRL2 induces inflammation and renal injury in the adult model of ischemia/reperfusion injury and in streptozotocin-induced diabetic mice [13, 17, 31].

Here, we investigated a potential pro-apoptotic role of TLR2 using neonatal Tlr2-/- mice we subjected to UUO. Firstly, we show that TLR2 expression is upregulated after UUO in neonatal mouse kidneys, which indicates a potential role of this receptor in obstructive nephropathy. This is in line with studies in adult mice, where TLR2 expression is markedly upregulated after UUO [32].

Secondly, by using neonatal Tlr2-/- mice we demonstrate that TLR2 mediates tubular and interstitial apoptosis in the obstructed neonatal kidney. Following UUO, neonatal kidneys of Tlr2-/- mice displayed markedly reduced abundance of tubular apoptotic nuclei, measured by a TUNEL assay. These apoptotic nuclei were predominantly present in distal tubular cells, which is in line with our published data on programmed cell death in the neonatal kidney [5]. In addition, interstitial apoptosis was also markedly reduced in neonatal Tlr2-/- mouse kidneys, suggesting their carriage of either less apoptotic infiltrating leukocytes or less apoptotic myofibroblasts and fibroblasts as compared to controls. In contrast, glomerular apoptosis did not differ between Tlr2-/- and WT kidneys. To potentially reinforce differences in tubular and interstitial apoptosis in WT and Tlr2-/- mice borne kidneys, caspase 8 expression was measured, but showed no difference between the lines in the neonatal kidneys of newborn mice undergoing UUO. Caspase-8 expression has limitations as an apoptotic marker, as it is a marker of the early phase of apoptosis [33]. In contrast, TUNEL staining has been designed to detect apoptotic cells that undergo extensive DNA degradation during the late stages of apoptosis [34]. Therefore, the differences between Tlr2-/- and WT kidneys may not be detectable during the initiation phase of apoptosis but become apparent in the late apoptotic stages of DNA degradation. In addition, as caspase-8 protein expression is measured for all compartments of the kidney by using whole neonatal kidney lysates for western blot analysis, a compartment-restricted expression of caspase 8 might have indicated differences we missed by our global approach. As our results were conflicting, we decided to include Bcl-2 as an anti-apoptotic marker [35, 36]. The increase of Bcl-2 expression in Tlr2-/- kidneys further confirms our findings that TLR2 mediates apoptosis in neonatal UUO. Our result “apoptosis reduction in Tlr2-/- mice” is in line with Leemans et al., who showed that TLR2 activates the apoptotic pathway in UUO-kidneys of adult mice [32]. The authors measured apoptosis through staining of active caspase-3 in cells, which was significantly reduced in Tlr2-/- mice after 7 days of ureteral obstruction. Unfortunately, we were not able to measure caspase-3 in neonatal kidneys most certainly as the abundance of this antigen was below the detection limit. In the neonatal model of unilateral ureteral obstruction, it is currently unknown how this Tlr2-/- associated apoptotic pathway is activated, caspase-3 might not be involved at all. TLR2, as a part of the innate immune system is activated by bacterial lipoproteins and signals for apoptosis through MyD88 via a pathway involving Fas-associated death domain protein and caspase-8 [37, 38]. Inflammation following UUO is not mediated by bacteria. UUO induces sterile inflammation, which is mediated by DAMPs, of which a variety might be able to activate the TLR2 mediated apoptotic pathway [23, 39]. High levels of apoptosis are associated with nephron loss in the developing kidney and thus the loss of renal function [40].

Besides apoptosis, necrosis and regulated necrosis are cell death mechanisms that are operative during UUO [41]. Previously we demonstrated necroptosis, a form of regulated necrosis, to be increased in the neonatal kidney undergoing UUO [5]. Here we demonstrate for the first time, that pyroptosis is also upregulated in the neonatal kidney with UUO. Pyroptosis is a gasdermin-mediated programmed cell death that involves the activation of inflammasomes by DAMPs [42]. Pyroptosis plays an important role in the progression of kidney disease and is involved in various kidney disease models [43]. Here we analyzed pyroptosis in neonatal Tlr2-/- and WT mice with UUO by the analyzing cleaved GSDMD and full-length GSDME abundances. The cleavage of GSDMD, or alternatively GSDME is a crucial step in the initiation of pyroptosis and pore formation [24]. In our study we show that UUO in neonatal kidneys induces. This observation is in accordance with findings in adult mice and rats subjected to UUO [44, 45]. However, pyroptosis was not different in Tlr2-/- mice as compared to WT controls suggesting that TLR2 is not involved in pyroptotic cell death following neonatal UUO.

TLR2 borne intracellular signal transduction is induced by sterile insult and triggers inflammation [46]. Inflammation is a major driver of UUO pathology associated with release of DAMPs and pro-inflammatory cytokines initiating it [23, 39]. It is currently unknown what DAMP induces apoptosis through TLR2. Numerous DAMPs are putative ligands of TLR2 [23, 47]. HMGB1 is involved in inflammasome activation as well as regulation of apoptosis [48, 49]. To investigate if HMGB1 mediates sterile inflammation in neonatal kidneys after UUO, we measured kidney borne HMGB1 expression levels. We show here for the first time that HMGB1 expression in neonatal kidneys did not increase after UUO. This contrasts with findings in kidneys of adult mice, where UUO caused a marked upregulation of kidney inherent HMGB1 [50] and may be explainable by differential expression in the course of kidney development. Nephrogenesis in mice starts at embryonic day 8 and is completed 2–3 weeks after birth. In contrast to adult UUO, neonatal UUO impairs kidney development and reduces nephron mass, as nephrogenesis is still going on. Thus, HMGB1 signaling may be differentially regulated in neonatal and adult mice with UUO. TNF, a pro-inflammatory cytokine, is another mediator of sterile inflammation following UUO. The activation of TLR2 principally leads to production of TNF [13, 51]. TNF is highly upregulated in kidneys of adult mice with UUO [52]. Contrary to our expectations, Tlr2-/- and WT mice did not upregulate TNF expression after UUO. Additionally, there were no differences between kidneys of the genotypes. Thus, sterile inflammation in neonatal kidneys after UUO seems to be mediated by neither HMGB1 nor TNF. Identification of DAMPs and mediators eliciting apoptosis in neonatal kidneys through TLR2 still is to be investigated.

In order to examine if TLR2 has an influence on proliferation in the neonatal UUO model, we analyzed relative abundances of KI67 positive tubular cells. We show that the number of proliferating tubules decreased following UUO. Whereas in adult UUO a decrease of proliferation was observed in Tlr2-/- kidneys in comparison to WT [32], in neonatal UUO lacked such dichotomy. Since neonatal kidney cells highly proliferate in general, slight differences between the two lines could have been overshadowed by the impact UUO has on nephrogenesis.

Morphological alterations in the tubular compartment play an important role in the pathogenesis of neonatal obstructive uropathy. Tubular atrophy is mainly a concern in proximal tubules, which is in line with previous results [5]. We were not able to observe differences between Tlr2-/- and WT neonatal kidneys regarding tubular atrophy. TLR2 does not influence tubular atrophy after neonatal UUO.

Renal interstitial fibrosis develops parallel to renal injury and sterile inflammation after neonatal UUO. Fibroblast density increases due to local proliferation of resident fibroblasts, the recruitment of fibrocytes and possibly epithelial-mesenchymal transition (EMT) [53]. T-lymphocytes and M2 macrophages are crucial in the development of renal fibrosis [54, 55]. It has been shown that in the adult UUO model M2 macrophages facilitate renal fibrosis [56]. Several studies have shown that depletion of T-cells after UUO in adult mice results in a reduction of renal fibrosis [57, 58]. Here, we observed a marked infiltration of M2-macrophages and T-cells after neonatal UUO. However, for all measured parameters there were no significant differences between Tlr2-/- and WT neonatal mice. This is in line with published data showing that a TLR2 knockout does not influence macrophage infiltration in adult UUO [32]. Expansion of fibrous connective tissue and abnormal deposition of extracellular matrix produced by myofibroblasts build the basis for fibrotic diseases. We measured the quantity of fibrotic collagen fibers in neonatal UUO kidneys, evaluated myofibroblasts by α-SMA staining and protein expression, and investigated the fibrotic marker TGF-β. The results show a significant increase of renal fibrosis in neonatal kidneys after UUO. We were not able to observe differences between Tlr2-/- and WT mice. Matrix metalloproteinases are involved in EMT following UUO. MMP-2 aggravates the expression of EMT-associated molecules and renal fibrosis in adult UUO [59]. In our study, MMP-2 increased noticeably after neonatal UUO, but without differences between Tlr2-/- and WT mice. By contrast, adult UUO kidneys showed a diminished expression of MMP-2 in Tlr2-/- mice. Thus, expression of MMP-2 after UUO may be differently regulated in neonatal and adult kidneys. Overall, TLR2 does not influence interstitial fibrosis in neonatal mouse kidneys with UUO.

Numerous studies showed involvement of TLR2 in acute kidney injury [13, 60]. Inhibition of TLR2 reduced the recruitment of NK cells, as well as neutrophil infiltration and renal damage to the kidney after IRI [60, 61]. TLR2 and its endogenous stress ligands are markedly upregulated in obstructed kidneys in adult mice [32, 62]. Our results demonstrate that TLR2 does play an essential role neither in kidney inflammation nor in the development of renal fibrosis following neonatal UUO. Recently, it has been shown that inhibition of both RAS and TLR2 has an additive ameliorative effect on UUO injury of the kidney [63]. Given this information it may be more effective to target additional pathways besides TLR2 in the obstructed kidney to ameliorate inflammation and fibrosis.

Conclusion

TLR2 plays an important role in mediating tubular and interstitial apoptosis in the neonatal kidney with obstruction. Inhibition of TLR2 in obstructive nephropathy could prevent apoptosis and save nephron mass, which would be otherwise irreversibly lost. Blocking TLR2 may be beneficial in the developing kidney with obstruction until the obstruction resolves or a surgical correction is performed. However, TLR2 does not influence inflammatory responses or development of renal fibrosis after UUO. Thus, a combination with other inhibitors may be of advantage.

Supporting information

S1 Raw images. Western blot raw images.

Uncropped western blot gel images for TLR2 and GAPDH in neonatal WT kidneys (on day 7 and 14 of life). * marks the section used in Fig 1. TLR2 and GAPDH were visualized separately, but they represent the same gel. Uncropped western blot gel images for TLR2 and GAPDH in neonatal WT kidneys (on day 7 and 14 of life). * marks the section used in Fig 1. For Bax Gel 2 was used. Uncropped western blot gel images for Caspase-8 and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 2. Caspase-8 and GAPDH were visualized separately, but they represent the same gel. Uncropped western blot gel images for GSDMD and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 3. GSDMD and GAPDH were visualized separately, but they represent the same gel. Uncropped western blot gel images for GSDME and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 3. GSDME and GAPDH were visualized separately, but they represent the same gel. Uncropped western blot gel images for HMGB1 and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 3. Uncropped western blot gel images for TNF-α and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 3. TNF-α and GAPDH were visualized separately (different exposer times), but they represent the same gel. Uncropped western blot gel images for Galectin-3, TGF-β, and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 6. Uncropped western blot gel images for α-SMA and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 6. Uncropped western blot gel images for MMP-2 and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 6. MMP-2 and GAPDH were visualized separately, but they represent the same gel.

(PDF)

Data Availability

The data from this study is available in a public repository (Zenodo) under this DOI: 10.5281/zenodo.8060419.

Funding Statement

The author(s) received specific funding for this work. Deutsche Forschungsgemeinschaft (DFG) 1257/5-1, Prof. Dr. Bärbel Lange-Sperandio.

References

  • 1.van der Ven AT, Connaughton DM, Ityel H, Mann N, Nakayama M, Chen J, et al. Whole-Exome Sequencing Identifies Causative Mutations in Families with Congenital Anomalies of the Kidney and Urinary Tract. J Am Soc Nephrol. 2018;29(9):2348–61. Epub 2018/08/26. doi: 10.1681/ASN.2017121265 ; PubMed Central PMCID: PMC6115658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Babu R, Vittalraj P, Sundaram S, Shalini S. Pathological changes in ureterovesical and ureteropelvic junction obstruction explained by fetal ureter histology. J Pediatr Urol. 2019;15(3):240 e1–e7. Epub 20190211. doi: 10.1016/j.jpurol.2019.02.001 . [DOI] [PubMed] [Google Scholar]
  • 3.Luyckx VA, Brenner BM. Clinical consequences of developmental programming of low nephron number. Anat Rec (Hoboken). 2020;303(10):2613–31. Epub 20191006. doi: 10.1002/ar.24270 . [DOI] [PubMed] [Google Scholar]
  • 4.Lange-Sperandio B. Pediatric Obstructive Uropathy. Pediatric Nephrology. Berlin Heidelberg: Springer-Verlag; 2022. p. 1369–98. [Google Scholar]
  • 5.Popper B, Rammer MT, Gasparitsch M, Singer T, Keller U, Doring Y, et al. Neonatal obstructive nephropathy induces necroptosis and necroinflammation. Sci Rep. 2019;9(1):18600. Epub 2019/12/11. doi: 10.1038/s41598-019-55079-w ; PubMed Central PMCID: PMC6901532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Meng XM, Mak TS, Lan HY. Macrophages in Renal Fibrosis. Adv Exp Med Biol. 2019;1165:285–303. doi: 10.1007/978-981-13-8871-2_13 . [DOI] [PubMed] [Google Scholar]
  • 7.Liu M, Zen K. Toll-Like Receptors Regulate the Development and Progression of Renal Diseases. Kidney Dis (Basel). 2021;7(1):14–23. Epub 2021/02/23. doi: 10.1159/000511947 ; PubMed Central PMCID: PMC7879300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Sepe V, Libetta C, Gregorini M, Rampino T. The innate immune system in human kidney inflammaging. J Nephrol. 2022;35(2):381–95. Epub 2021/11/27. doi: 10.1007/s40620-021-01153-4 ; PubMed Central PMCID: PMC8617550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fitzgerald KA, Kagan JC. Toll-like Receptors and the Control of Immunity. Cell. 2020;180(6):1044–66. Epub 20200311. doi: 10.1016/j.cell.2020.02.041 ; PubMed Central PMCID: PMC9358771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Feldman N, Rotter-Maskowitz A, Okun E. DAMPs as mediators of sterile inflammation in aging-related pathologies. Ageing Res Rev. 2015;24(Pt A):29–39. Epub 20150129. doi: 10.1016/j.arr.2015.01.003 . [DOI] [PubMed] [Google Scholar]
  • 11.Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol. 2014;14(8):546–58. doi: 10.1038/nri3713 . [DOI] [PubMed] [Google Scholar]
  • 12.Lin Z, Lin H, Li W, Huang Y, Dai H. Complement Component C3 Promotes Cerebral Ischemia/Reperfusion Injury Mediated by TLR2/NFkappaB Activation in Diabetic Mice. Neurochem Res. 2018;43(8):1599–607. Epub 20180613. doi: 10.1007/s11064-018-2574-z . [DOI] [PubMed] [Google Scholar]
  • 13.Mohamed ME, Kandeel M, Abd El-Lateef HM, El-Beltagi HS, Younis NS. The Protective Effect of Anethole against Renal Ischemia/Reperfusion: The Role of the TLR2,4/MYD88/NFkappaB Pathway. Antioxidants (Basel). 2022;11(3). Epub 20220311. doi: 10.3390/antiox11030535 ; PubMed Central PMCID: PMC8944622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Yiu WH, Lin M, Tang SC. Toll-like receptor activation: from renal inflammation to fibrosis. Kidney Int Suppl (2011). 2014;4(1):20–5. doi: 10.1038/kisup.2014.5 ; PubMed Central PMCID: PMC4536963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.van Bergenhenegouwen J, Plantinga TS, Joosten LA, Netea MG, Folkerts G, Kraneveld AD, et al. TLR2 & Co: a critical analysis of the complex interactions between TLR2 and coreceptors. J Leukoc Biol. 2013;94(5):885–902. Epub 20130829. doi: 10.1189/jlb.0113003 . [DOI] [PubMed] [Google Scholar]
  • 16.Habib R. Multifaceted roles of Toll-like receptors in acute kidney injury. Heliyon. 2021;7(3):e06441. Epub 20210308. doi: 10.1016/j.heliyon.2021.e06441 ; PubMed Central PMCID: PMC7944035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ma J, Wu H, Zhao CY, Panchapakesan U, Pollock C, Chadban SJ. Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. Int J Clin Exp Pathol. 2014;7(2):481–95. Epub 2014/02/20. ; PubMed Central PMCID: PMC3925893. [PMC free article] [PubMed] [Google Scholar]
  • 18.Liu C, Shen Y, Huang L, Wang J. TLR2/caspase-5/Panx1 pathway mediates necrosis-induced NLRP3 inflammasome activation in macrophages during acute kidney injury. Cell Death Discov. 2022;8(1):232. Epub 20220426. doi: 10.1038/s41420-022-01032-2 ; PubMed Central PMCID: PMC9042857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Paveljsek D, Ivicak-Kocjan K, Treven P, Bencina M, Jerala R, Rogelj I. Distinctive probiotic features share common TLR2-dependent signalling in intestinal epithelial cells. Cell Microbiol. 2021;23(1):e13264. Epub 20201001. doi: 10.1111/cmi.13264 ; PubMed Central PMCID: PMC7757178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Yang H, Wang H, Andersson U. Targeting Inflammation Driven by HMGB1. Front Immunol. 2020;11:484. Epub 20200320. doi: 10.3389/fimmu.2020.00484 ; PubMed Central PMCID: PMC7099994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.He M, Bianchi ME, Coleman TR, Tracey KJ, Al-Abed Y. Exploring the biological functional mechanism of the HMGB1/TLR4/MD-2 complex by surface plasmon resonance. Mol Med. 2018;24(1):21. Epub 20180510. doi: 10.1186/s10020-018-0023-8 ; PubMed Central PMCID: PMC6085627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chen Q, Guan X, Zuo X, Wang J, Yin W. The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta Pharm Sin B. 2016;6(3):183–8. Epub 2016/05/14. doi: 10.1016/j.apsb.2016.02.004 ; PubMed Central PMCID: PMC4856949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wyczanska M, Lange-Sperandio B. DAMPs in Unilateral Ureteral Obstruction. Front Immunol. 2020;11:581300. Epub 20201007. doi: 10.3389/fimmu.2020.581300 ; PubMed Central PMCID: PMC7575708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Liu P, Zhang Z, Li Y. Relevance of the Pyroptosis-Related Inflammasome Pathway in the Pathogenesis of Diabetic Kidney Disease. Front Immunol. 2021;12:603416. Epub 2021/03/12. doi: 10.3389/fimmu.2021.603416 ; PubMed Central PMCID: PMC7937695. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Braga TT, Correa-Costa M, Guise YF, Castoldi A, de Oliveira CD, Hyane MI, et al. MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages. Mol Med. 2012;18:1231–9. Epub 2012/07/11. doi: 10.2119/molmed.2012.00131 ; PubMed Central PMCID: PMC3510298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Spiller S, Dreher S, Meng G, Grabiec A, Thomas W, Hartung T, et al. Cellular recognition of trimyristoylated peptide or enterobacterial lipopolysaccharide via both TLR2 and TLR4. J Biol Chem. 2007;282(18):13190–8. Epub 20070312. doi: 10.1074/jbc.M610340200 . [DOI] [PubMed] [Google Scholar]
  • 27.Lange-Sperandio B, Schimpgen K, Rodenbeck B, Chavakis T, Bierhaus A, Nawroth P, et al. Distinct roles of Mac-1 and its counter-receptors in neonatal obstructive nephropathy. Kidney Int. 2006;69(1):81–8. Epub 2005/12/24. doi: 10.1038/sj.ki.5000017 . [DOI] [PubMed] [Google Scholar]
  • 28.Gasparitsch M, Schieber A, Schaubeck T, Keller U, Cattaruzza M, Lange-Sperandio B. Tyrphostin AG490 reduces inflammation and fibrosis in neonatal obstructive nephropathy. PLoS One. 2019;14(12):e0226675. Epub 2019/12/18. doi: 10.1371/journal.pone.0226675 ; PubMed Central PMCID: PMC6917291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Orning P, Lien E. Multiple roles of caspase-8 in cell death, inflammation, and innate immunity. J Leukoc Biol. 2021;109(1):121–41. Epub 2020/06/13. doi: 10.1002/JLB.3MR0420-305R ; PubMed Central PMCID: PMC8664275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Krivan S, Kapelouzou A, Vagios S, Tsilimigras DI, Katsimpoulas M, Moris D, et al. Increased expression of Toll-like receptors 2, 3, 4 and 7 mRNA in the kidney and intestine of a septic mouse model. Sci Rep. 2019;9(1):4010. Epub 20190308. doi: 10.1038/s41598-019-40537-2 ; PubMed Central PMCID: PMC6408498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Yuan Y, Liu Y, Sun M, Ye H, Feng Y, Liu Z, et al. Aggravated renal fibrosis is positively associated with the activation of HMGB1-TLR2/4 signaling in STZ-induced diabetic mice. Open Life Sci. 2022;17(1):1451–61. Epub 2022/12/01. doi: 10.1515/biol-2022-0506 ; PubMed Central PMCID: PMC9658007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Leemans JC, Butter LM, Pulskens WP, Teske GJ, Claessen N, van der Poll T, et al. The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury. PLoS One. 2009;4(5):e5704. Epub 2009/05/30. doi: 10.1371/journal.pone.0005704 ; PubMed Central PMCID: PMC2682651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. Epub 2007/06/15. doi: 10.1080/01926230701320337 ; PubMed Central PMCID: PMC2117903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kyrylkova K, Kyryachenko S, Leid M, Kioussi C. Detection of apoptosis by TUNEL assay. Methods Mol Biol. 2012;887:41–7. Epub 2012/05/09. doi: 10.1007/978-1-61779-860-3_5 . [DOI] [PubMed] [Google Scholar]
  • 35.Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37(3):299–310. doi: 10.1016/j.molcel.2010.01.025 ; PubMed Central PMCID: PMC3222298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Zhang G, Oldroyd SD, Huang LH, Yang B, Li Y, Ye R, et al. Role of apoptosis and Bcl-2/Bax in the development of tubulointerstitial fibrosis during experimental obstructive nephropathy. Exp Nephrol. 2001;9(2):71–80. doi: 10.1159/000052597 . [DOI] [PubMed] [Google Scholar]
  • 37.Aliprantis AO, Yang RB, Weiss DS, Godowski P, Zychlinsky A. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J. 2000;19(13):3325–36. Epub 2000/07/06. doi: 10.1093/emboj/19.13.3325 ; PubMed Central PMCID: PMC313930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Nguyen TNY, Padungros P, Wongsrisupphakul P, Sa-Ard-Iam N, Mahanonda R, Matangkasombut O, et al. Cell wall mannan of Candida krusei mediates dendritic cell apoptosis and orchestrates Th17 polarization via TLR-2/MyD88-dependent pathway. Sci Rep. 2018;8(1):17123. Epub 20181120. doi: 10.1038/s41598-018-35101-3 ; PubMed Central PMCID: PMC6244250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20(2):95–112. Epub 20190926. doi: 10.1038/s41577-019-0215-7 . [DOI] [PubMed] [Google Scholar]
  • 40.Priante G, Gianesello L, Ceol M, Del Prete D, Anglani F. Cell Death in the Kidney. Int J Mol Sci. 2019;20(14). Epub 20190723. doi: 10.3390/ijms20143598 ; PubMed Central PMCID: PMC6679187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Xiao X, Du C, Yan Z, Shi Y, Duan H, Ren Y. Inhibition of Necroptosis Attenuates Kidney Inflammation and Interstitial Fibrosis Induced By Unilateral Ureteral Obstruction. Am J Nephrol. 2017;46(2):131–8. Epub 20170720. doi: 10.1159/000478746 . [DOI] [PubMed] [Google Scholar]
  • 42.Sarhan M, von Massenhausen A, Hugo C, Oberbauer R, Linkermann A. Immunological consequences of kidney cell death. Cell Death Dis. 2018;9(2):114. Epub 2018/01/27. doi: 10.1038/s41419-017-0057-9 ; PubMed Central PMCID: PMC5833784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Zhang KJ, Wu Q, Jiang SM, Ding L, Liu CX, Xu M, et al. Pyroptosis: A New Frontier in Kidney Diseases. Oxid Med Cell Longev. 2021;2021:6686617. Epub 2021/05/20. doi: 10.1155/2021/6686617 ; PubMed Central PMCID: PMC8102120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Zhang Y, Zhang R, Han X. Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis. Inflamm Res. 2021;70(5):543–52. Epub 2021/04/15. doi: 10.1007/s00011-021-01457-y . [DOI] [PubMed] [Google Scholar]
  • 45.Wu M, Xia W, Jin Q, Zhou A, Wang Q, Li S, et al. Gasdermin E Deletion Attenuates Ureteral Obstruction- and 5/6 Nephrectomy-Induced Renal Fibrosis and Kidney Dysfunction. Front Cell Dev Biol. 2021;9:754134. Epub 2021/11/09. doi: 10.3389/fcell.2021.754134 ; PubMed Central PMCID: PMC8567074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Shen H, Kreisel D, Goldstein DR. Processes of sterile inflammation. J Immunol. 2013;191(6):2857–63. Epub 2013/09/10. doi: 10.4049/jimmunol.1301539 ; PubMed Central PMCID: PMC3787118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Schattner M. Sleep like a bear. Science. 2023;380(6641):133–4. Epub 20230413. doi: 10.1126/science.adh3276 . [DOI] [PubMed] [Google Scholar]
  • 48.Yang H, Wang H, Chavan SS, Andersson U. High Mobility Group Box Protein 1 (HMGB1): The Prototypical Endogenous Danger Molecule. Mol Med. 2015;21 Suppl 1:S6–S12. Epub 2015/11/26. doi: 10.2119/molmed.2015.00087 ; PubMed Central PMCID: PMC4661054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Foglio E, Pellegrini L, Germani A, Russo MA, Limana F. HMGB1-mediated apoptosis and autophagy in ischemic heart diseases. Vasc Biol. 2019;1(1):H89–H96. Epub 20190812. doi: 10.1530/VB-19-0013 ; PubMed Central PMCID: PMC7439920. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Tian S, Zhang L, Tang J, Guo X, Dong K, Chen SY. HMGB1 exacerbates renal tubulointerstitial fibrosis through facilitating M1 macrophage phenotype at the early stage of obstructive injury. Am J Physiol Renal Physiol. 2015;308(1):F69–75. Epub 2014/11/08. doi: 10.1152/ajprenal.00484.2014 ; PubMed Central PMCID: PMC4281691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Papadopoulos G, Weinberg EO, Massari P, Gibson FC 3rd, Wetzler LM, Morgan EF, et al. Macrophage-specific TLR2 signaling mediates pathogen-induced TNF-dependent inflammatory oral bone loss. J Immunol. 2013;190(3):1148–57. Epub 2012/12/25. doi: 10.4049/jimmunol.1202511 ; PubMed Central PMCID: PMC3549226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Al-Lamki RS, Mayadas TN. TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney Int. 2015;87(2):281–96. Epub 20140820. doi: 10.1038/ki.2014.285 . [DOI] [PubMed] [Google Scholar]
  • 53.Zhou J, Jiang H, Jiang H, Fan Y, Zhang J, Ma X, et al. The ILEI/LIFR complex induces EMT via the Akt and ERK pathways in renal interstitial fibrosis. J Transl Med. 2022;20(1):54. Epub 20220129. doi: 10.1186/s12967-022-03265-2 ; PubMed Central PMCID: PMC8800269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Braga TT, Agudelo JS, Camara NO. Macrophages During the Fibrotic Process: M2 as Friend and Foe. Front Immunol. 2015;6:602. Epub 2015/12/05. doi: 10.3389/fimmu.2015.00602 ; PubMed Central PMCID: PMC4658431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15(3):144–58. Epub 20190128. doi: 10.1038/s41581-019-0110-2 . [DOI] [PubMed] [Google Scholar]
  • 56.Pan B, Liu G, Jiang Z, Zheng D. Regulation of renal fibrosis by macrophage polarization. Cell Physiol Biochem. 2015;35(3):1062–9. Epub 2015/02/11. doi: 10.1159/000373932 . [DOI] [PubMed] [Google Scholar]
  • 57.Tapmeier TT, Fearn A, Brown K, Chowdhury P, Sacks SH, Sheerin NS, et al. Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int. 2010;78(4):351–62. Epub 2010/06/18. doi: 10.1038/ki.2010.177 . [DOI] [PubMed] [Google Scholar]
  • 58.Liu L, Kou P, Zeng Q, Pei G, Li Y, Liang H, et al. CD4+ T Lymphocytes, especially Th2 cells, contribute to the progress of renal fibrosis. Am J Nephrol. 2012;36(4):386–96. Epub 2012/10/12. doi: 10.1159/000343283 . [DOI] [PubMed] [Google Scholar]
  • 59.Du X, Shimizu A, Masuda Y, Kuwahara N, Arai T, Kataoka M, et al. Involvement of matrix metalloproteinase-2 in the development of renal interstitial fibrosis in mouse obstructive nephropathy. Lab Invest. 2012;92(8):1149–60. Epub 2012/05/23. doi: 10.1038/labinvest.2012.68 . [DOI] [PubMed] [Google Scholar]
  • 60.Kim HJ, Park SJ, Koo S, Cha HJ, Lee JS, Kwon B, et al. Inhibition of kidney ischemia-reperfusion injury through local infusion of a TLR2 blocker. J Immunol Methods. 2014;407:146–50. Epub 2014/04/01. doi: 10.1016/j.jim.2014.03.014 . [DOI] [PubMed] [Google Scholar]
  • 61.Kim HJ, Lee JS, Kim A, Koo S, Cha HJ, Han JA, et al. TLR2 signaling in tubular epithelial cells regulates NK cell recruitment in kidney ischemia-reperfusion injury. J Immunol. 2013;191(5):2657–64. Epub 2013/08/02. doi: 10.4049/jimmunol.1300358 . [DOI] [PubMed] [Google Scholar]
  • 62.Skuginna V, Lech M, Allam R, Ryu M, Clauss S, Susanti HE, et al. Toll-like receptor signaling and SIGIRR in renal fibrosis upon unilateral ureteral obstruction. PLoS One. 2011;6(4):e19204. Epub 2011/05/06. doi: 10.1371/journal.pone.0019204 ; PubMed Central PMCID: PMC3081345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Chung S, Jeong JY, Chang YK, Choi DE, Na KR, Lim BJ, et al. Concomitant inhibition of renin angiotensin system and Toll-like receptor 2 attenuates renal injury in unilateral ureteral obstructed mice. Korean J Intern Med. 2016;31(2):323–34. Epub 2016/03/05. doi: 10.3904/kjim.2015.004 ; PubMed Central PMCID: PMC4773720. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Franziska Theilig

17 May 2023

PONE-D-23-12099TLR2 mediates renal apoptosis in neonatal mice subjected experimentally to obstructive nephropathyPLOS ONE

Dear Dr. Lange-Sperandio,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 01 2023 11:59PM . If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Franziska Theilig

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. To comply with PLOS ONE submissions requirements, in your Methods section, please provide additional information regarding the experiments involving animals and ensure you have included details on (1) methods of sacrifice, and (2) efforts to alleviate suffering.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. Thank you for stating the following financial disclosure: 

   "The author(s) received no specific funding for this work."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. Please amend the manuscript submission data (via Edit Submission) to include author Dr. Ursula Keller.

7. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. 

  

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

8. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this manuscript, a series of studies concerning the important role of TLR2 in the neonatal kidney with obstruction have been showed. In this study, TLR2’s crucial role in mediating tubular and interstitial apoptosis is highlighted, which, as authors mentioned in the manuscript, may shade light on developing new treatment approaches to congenital obstructive nephropathy in the future. It is worth valuing for the efforts made by the researchers, however, there are several points need to be addressed.

1. The subject of this manuscript is TLR2 mediates renal apoptosis in neonatal mice subjected experimentally to obstructive nephropathy. However, in this manuscript, the proportion of narrative and experimental evidence of renal apoptosis is low, while other results that do not differ are slightly more discussed, indicating a shift in emphasis in the article. Authors could increase the types of experiments on renal apoptosis or dig deeper into the mechanism of TLR2 on renal apoptosis to make full-text logic more clarity.

2. Result I and II are both results about the center of the article, which is renal apoptosis, but they have somewhat smaller sample sizes, even less than the sample size of the undifferentiated results. It is recommended that researchers increase the sample size to make the article data more convincing.

3. The method section of the article does not describe the source of the knockout mice, and it is suggested to add a description to increase the credibility of the data. Moreover, the references of the article are old, it is recommended to use the journal literature within the last 3 years or 5 years if possible.

Reviewer #2: 1) In Figure 1, the expression of TLR2 on d14 was less than d7 in the sham group, and in the UUO group the TLR2 expression on d7 and d14 was similar. How to explain this result?

2) In figure 2F and 3, there were 8 groups, but histogram had only 4. What did * mean, which two groups’ comparison in Figure 2E-F, Figure 3A-D, and so on? More details are needed.

3) From the WB image in Figure 6B, there was no difference between d7 and d14 in UUO or Tlr2-/- group, which was different from the histogram result, and not in line with UUO progression. Besides, in the sham group, the expression of Galectin-3 on d14 was significantly reduced when compared to d7, why the expression of Galectin-3 in the sham group reduced.

4) In lines 78-80, the author described the protective effect of Tlr2-/- on inflammation and tubular injury. But the experiment results showed that Tlr2-/- had no influence on tubular inflammation, injury, or fibrosis. If it is paradox?

5) There was too much result explanation in the discussion of the manuscript. The experiment results showed TLR2 participated in tubular epithelial apoptosis, but had no influence on renal injury or fibrosis, neither proliferation nor inflammation. So what’s the role of TLR2 in UUO induced renal injury or fibrosis? More information about TLR2 on UUO model are needed.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: 1.docx

PLoS One. 2023 Nov 28;18(11):e0294142. doi: 10.1371/journal.pone.0294142.r002

Author response to Decision Letter 0


30 Jun 2023

Reviewer 1

1) The subject of this manuscript is TLR2 mediates renal apoptosis in neonatal mice subjected experimentally to obstructive nephropathy. However, in this manuscript, the proportion of narrative and experimental evidence of renal apoptosis is low, while other results that do not differ are slightly more discussed, indicating a shift in emphasis in the article. Authors could increase the types of experiments on renal apoptosis or dig deeper into the mechanism of TLR2 on renal apoptosis to make full-text logic more clarity.

Ad 1) Thank you for this important comment. We extended the section about apoptosis in our manuscript giving this topic the spotlight. You can find the additional text in lines 423-430. It reads now: ‘TLR2, as a part of the innate immune system is activated by bacterial lipoproteins and signals for apoptosis through MyD88 via a pathway involving Fas-associated death domain protein and caspase-8. Inflammation following UUO is not mediated by bacteria. UUO induces sterile inflammation, which is mediated by DAMPs, of which a variety might be able to activate the TLR2 mediated apoptotic pathway. High levels of apoptosis are associated with nephron loss in the developing kidney and thus the loss of renal function.’

We also reduced the sections in the discussion part regarding the remaining results.

2) Result I and II are both results about the center of the article, which is renal apoptosis, but they have somewhat smaller sample sizes, even less than the sample size of the undifferentiated results. It is recommended that researchers increase the sample size to make the article data more convincing.

Ad 2) The sample sizes for immunohistochemical staining are n=8 per group for every used staining method, in the case of apoptosis it’s the TUNEL staining. As for the western blot analysis, being here the analysis of caspase-8, we were only able to use 3 samples per analysis per group. Usually with adult mice it is possible to split the kidneys in parts for different analyses. However, we work with neonatal mice, of which kidney weights range on average between 15 mg at day 3 of life and only 65 mg on day 14 (sham-operated controls). The body weight of these neonatal mice also lies only between around 1.7 g on the second day of life, 4 g on day 7, and 7.3 g on day 14 of life [Lange-Sperandio B et al. Leukocytes Induce Epithelial to Mesenchymal Transition after Unilateral Ureteral Obstruction in Neonatal Mice. Am. J. Clin. Pathol. 2007; 861-871]. We have to perform a lysis of the whole kidney for enough material for our analyses. To ensure a large analytic range we are bound to limit our sample size used for protein analysis.

3) The method section of the article does not describe the source of the knockout mice, and it is suggested to add a description to increase the credibility of the data. Moreover, the references of the article are old, it is recommended to use the journal literature within the last 3 years or 5 years if possible.

Ad 3) Thank you very much for your valuable suggestions. We added the source of the knockout mice to our manuscript, see lines 102-104. It reads now: ‘The Tlr2-/- mouse strain used (and crossed with other Tlr ko strains) has been generated by Deltagen, Cal, USA, and provided to CK through Tularik (merged into Amgen in the aftermath).’

We also updated the literature accordingly.

Reviewer 2

1) In Figure 1, the expression of TLR2 on d14 was less than d7 in the sham group, and in the UUO group the TLR2 expression on d7 and d14 was similar. How to explain this result?

Thank you for your comments.

Ad 1) Thank you for this important comment. We work here with neonatal mice, in which nephrogenesis is still ongoing after birth. The changes in the TLR2 expression may be developmentally differently regulated. Studies have shown that the expression of TLR2 during organ development changes with time and depends heavily on the organ [Harju K, Glumoff V, Hallman M. Ontogeny of Toll-like receptors Tlr2 and Tlr4 in mice. Pediatr Res. 2001;49(1):81-3.]. If we than combine the results of the sham-operated and UUO kidneys, we see that the increase of TLR2 following UUO on d14 is indeed higher than on d7, which is consistent with the severity of the injury.

2) In figure 2F and 3, there were 8 groups, but histogram had only 4. What did * mean, which two groups’ comparison in Figure 2E-F, Figure 3A-D, and so on? More details are needed.

Ad 2) Thank you very much for the question. We show the results of our analyses as x-fold change above sham-operated controls. This form of presentation allows us to show the actual impact of UUO with the sham-measurements as the basis. We divide the UUO measurements by the average of the sham measurements to achieve the results we present at the end. This way we reduce the presented groups to 4 (WT vs TLR2 x-fold above sham for d7 and d14). The * displayed alone here indicates that the differences between sham and UUO are significant. We updated the figure legends for more clarification, see lines 263-264, 290-291, 316-317, 367, 376-377. It reads now: ‘Standalone * represents significant differences between Sham and UUO results.’

3) From the WB image in Figure 6B, there was no difference between d7 and d14 in UUO or Tlr2-/- group, which was different from the histogram result, and not in line with UUO progression. Besides, in the sham group, the expression of Galectin-3 on d14 was significantly reduced when compared to d7, why the expression of Galectin-3 in the sham group reduced.

Ad 3) The differences we show here are x-fold above sham, so the decrease of α-SMA in the sham-operated controls impacts the shown results. The increase of α-SMA following UUO based on the sham results on d14 is higher than the increase on d7. This decrease of α-SMA has been shown before [Gasparitsch M et al. RAGE-mediated interstitial fibrosis in neonatal obstructive nephropathy is independent of NF-kappaB activation. Kidney Int. 2013;84(5):911-9.] in the sham-operated kidneys and is part of the ongoing nephrogenesis with mesenchymal-to-epithelial transition (MET). MET is a biological process that involves the transition from mesenchymal cells to epithelial cells as part of normal development. The drastic decrease observed in the expression of Galectin-3 is an effect of differently regulated proteins in the course of the development of the kidney. Galectin-3 plays a role in nephrogenesis [Winyard PJ et al. Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases. J Am Soc Nephrol. 1997;8(11):1647-57.]. In the metanephros, the adult kidney precursor, galectin-3 was detected in the apical domains of ureteric bud branches, and there was intense expression in fetal medullary and papillary collecting ducts in both the cytoplasm and plasma membranes. Developmentally important proteins are expressed highly during nephrogenesis and decline with time, as the kidney development is gradually completed.

4) In lines 78-80, the author described the protective effect of Tlr2-/- on inflammation and tubular injury. But the experiment results showed that Tlr2-/- had no influence on tubular inflammation, injury, or fibrosis. If it is paradox?

Ad 4) We appreciate the comment of the referee. The protective effect of Tlr2-/- was shown in adult mice. However, we conducted our research on neonatal mice. We were able to show previously that neonatal mice can respond differently to UUO injury in comparison to adult mice [Kubik MJ et al. Renal developmental genes are differentially regulated after unilateral ureteral obstruction in neonatal and adult mice. Sci Rep. 2020;10(1):19302.]. We added „adult“ to this text part for further clarification.

5) There was too much result explanation in the discussion of the manuscript. The experiment results showed TLR2 participated in tubular epithelial apoptosis, but had no influence on renal injury or fibrosis, neither proliferation nor inflammation. So what’s the role of TLR2 in UUO induced renal injury or fibrosis? More information about TLR2 on UUO model are needed.

Ad 5) Thank you for pointing this out. We reduced the discussion text as suggested. TLR2 seems to play a minor role in neonatal UUO regarding renal injury, fibrosis, and inflammation. It is possible that alternative or additional signaling pathways are activated in neonatal mice following UUO and the knockout of TLR2 is not effective in ameliorating the whole injury, but just apoptosis. Apoptosis itself is a non-inflammatory cell death and its inhibition does not influence inflammation [Roychowdhury S, Chiang DJ, Mandal P, McMullen MR, Liu X, Cohen JI, et al. Inhibition of apoptosis protects mice from ethanol-mediated acceleration of early markers of CCl4-induced fibrosis but not steatosis or inflammation. Alcohol Clin Exp Res. 2012;36(7):1139-47]. The inhibition of other pathways in addition of TLR2 could give promising results and help to reduce the injury done to the kidneys until obstruction is relieved.

Attachment

Submitted filename: Response to Reviewers.pdf

Decision Letter 1

Franziska Theilig

12 Sep 2023

PONE-D-23-12099R1TLR2 mediates renal apoptosis in neonatal mice subjected experimentally to obstructive nephropathyPLOS ONE

Dear Dr. Lange-Sperandio,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

One reviewer still has raised some question, which I would like you to answer before acceptance.

Please submit your revised manuscript by Oct 27 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Franziska Theilig

Academic Editor

PLOS ONE

Journal Requirements:

1. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you to the authors for answering all my questions carefully and patiently.

The authors have added the section in the center of the article and shortened the discussion of the remaining sections accordingly, and I fully understand the explanation of the sample size; there is indeed a huge difference between neonatal and adult mice, and it is also a great thing to allocate the experimental materials wisely. Many thanks for adding the source of the knockout rats, which makes the source of the article's data even more compelling, but there are a few other minor problems with the article:

1、 In result 1“Neonatal UUO induces protein expression of TLR2”,authors only showed the results of Western Blotting experiment, I suggest that authors can add the pathological results of the sham group versus the UUO group,moreover,authors are able to testify the indicators of renal fibrosis.

2、 In result 2“TLR2 mediates tubular and interstitial apoptosis in neonatal kidneys with UUO”;Although authors used the knockout mouse,did not demonstrate the evidences of decreasing the expression of TlR2.On the other hand,the indicators of Western Blotting verifying apoptosis are insufficient,authors can add Bax and Bcl-2 etc.

3、 The results of subsequent experiments by the author were all negative,however,displaying experiments were inadequate to demonstrate the regulation of TLR2 on renal apoptosis.I recommend authors to supplement experiments to make the paper more logical and compact.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Nov 28;18(11):e0294142. doi: 10.1371/journal.pone.0294142.r004

Author response to Decision Letter 1


19 Oct 2023

Response to Reviewers

Reviewer 1

1) In result 1“Neonatal UUO induces protein expression of TLR2”, authors only showed the results of Western Blotting experiment, I suggest that authors can add the pathological results of the sham group versus the UUO group, moreover, authors are able to testify the indicators of renal fibrosis.

Ad 1) Thank you for this valuable comment. We absolutely agree that it is important to show the pathological results of UUO. The pathological effects of neonatal UUO are thoroughly studied [1]. We indicate these changes in our study as well. The standalone asterisks (*) in the bar plots indicate that the results shown were significantly different between the sham and UUO group. This way we are able to show the overall pathology of neonatal UUO and the differences between Tlr2-/- and WT mice in one plot.

2) In result 2 “TLR2 mediates tubular and interstitial apoptosis in neonatal kidneys with UUO”; Although authors used the knockout mouse, did not demonstrate the evidence of decreasing the expression of TLR2. On the other hand, the indicators of Western Blotting verifying apoptosis are insufficient, authors can add Bax and Bcl-2 etc.

Ad 2) Thank you for this important suggestion. We agree that evidence that the knock-out mice indeed do not express TLR2 is essential. We added to figure 1 the results of a western blot analysis showing, that in comparison to WT the Tlr2-/- mice do not express TLR2 protein. We also added a text to the results section regarding this analysis, you can find it in lines 224-225 and it reads: “This analysis was also used to confirm that Tlr2-/- mice indeed did not express TLR2 (Fig 1B).”

Thank you for the comment regarding additional apoptosis experiments. We performed additional western blots of Bcl-2 and Bax. The protein expression of Bcl2 after ureteral obstruction increased significantly in Tlr2-/- mice at day 14 of life in comparison to WT. As Bcl-2 is known to suppress apoptosis [2], this confirms our findings, that TLR2 mediates apoptosis in the UUO model and that Tlr2-/- kidneys show less apoptosis after neonatal UUO in comparison to WT. We also measured the protein expression of Bax, an apoptosis activator [2] in neonatal mice kidneys. There was no significant difference in Bax expression between Tlr2-/- and WT mice. We added the results of both analyses to figure 3 and included these in the results and discussion sections in lines 259-264 and 441-443. It reads now: “For further analysis of cell death in our model we analyzed the anti-apoptotic marker Bcl-2 and the pro-apoptotic marker Bax using western blot (Fig 3). Neonatal Tlr2-/- mice showed a higher expression of Bcl-2 at day 14 in comparison to WT (Fig 3A), confirming that TLR2 mediates apoptosis in the neonatal model of obstructive nephropathy. Bax expression increased following UUO at day 14, without significant differences between Tlr2-/- and WT kidneys.” And (discussion) “As our results were conflicting, we decided to include Bcl-2 as an anti-apoptotic marker [2, 3]. The increase of Bcl-2 expression in Tlr2-/- kidneys further confirms our findings that TLR2 mediates apoptosis in neonatal UUO.”.

3) The results of subsequent experiments by the author were all negative, however, displaying experiments were inadequate to demonstrate the regulation of TLR2 on renal apoptosis. I recommend authors to supplement experiments to make the paper more logical and compact.

Ad 3) Thank you for this valuable insight. We agree that the displayed results were not strong enough to show that TLR2 mediates apoptosis in the neonatal UUO model. We hope that the additional experiments we performed are sufficient to confirm our findings in this study. We think that these results have important implications for future research on TLR2.

1. Chevalier, R.L., M.S. Forbes, and B.A. Thornhill, Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int, 2009. 75(11): p. 1145-1152.

2. Chipuk, J.E., et al., The BCL-2 family reunion. Mol Cell, 2010. 37(3): p. 299-310.

3. Zhang, G., et al., Role of apoptosis and Bcl-2/Bax in the development of tubulointerstitial fibrosis during experimental obstructive nephropathy. Exp Nephrol, 2001. 9(2): p. 71-80.

Attachment

Submitted filename: Response to Reviewers.doc

Decision Letter 2

Franziska Theilig

26 Oct 2023

TLR2 mediates renal apoptosis in neonatal mice subjected experimentally to obstructive nephropathy

PONE-D-23-12099R2

Dear Dr. Lange-Sperandio,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Franziska Theilig

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Franziska Theilig

16 Nov 2023

PONE-D-23-12099R2

TLR2 mediates renal apoptosis in neonatal mice subjected experimentally to obstructive nephropathy

Dear Dr. Lange-Sperandio:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Franziska Theilig

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Raw images. Western blot raw images.

    Uncropped western blot gel images for TLR2 and GAPDH in neonatal WT kidneys (on day 7 and 14 of life). * marks the section used in Fig 1. TLR2 and GAPDH were visualized separately, but they represent the same gel. Uncropped western blot gel images for TLR2 and GAPDH in neonatal WT kidneys (on day 7 and 14 of life). * marks the section used in Fig 1. For Bax Gel 2 was used. Uncropped western blot gel images for Caspase-8 and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 2. Caspase-8 and GAPDH were visualized separately, but they represent the same gel. Uncropped western blot gel images for GSDMD and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 3. GSDMD and GAPDH were visualized separately, but they represent the same gel. Uncropped western blot gel images for GSDME and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 3. GSDME and GAPDH were visualized separately, but they represent the same gel. Uncropped western blot gel images for HMGB1 and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 3. Uncropped western blot gel images for TNF-α and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 3. TNF-α and GAPDH were visualized separately (different exposer times), but they represent the same gel. Uncropped western blot gel images for Galectin-3, TGF-β, and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 6. Uncropped western blot gel images for α-SMA and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 6. Uncropped western blot gel images for MMP-2 and GAPDH in neonatal WT and TLR2-/- kidneys (on day 7 and 14 of life). * marks the section used in Fig 6. MMP-2 and GAPDH were visualized separately, but they represent the same gel.

    (PDF)

    Attachment

    Submitted filename: 1.docx

    Attachment

    Submitted filename: Response to Reviewers.pdf

    Attachment

    Submitted filename: Response to Reviewers.doc

    Data Availability Statement

    The data from this study is available in a public repository (Zenodo) under this DOI: 10.5281/zenodo.8060419.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES